2025³â 08¿ù 14ÀÏ ¸ñ¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Business

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

ELIQUENT Life Sciences Announces: Rob Wojciechowski Named Chief Operations Officer

´º½ºÀÏÀÚ: 2025-02-16

WASHINGTON -- ELIQUENT Life Sciences (ELIQUENT), a global regulatory, quality, and safety consulting firm, announced the appointment of Rob Wojciechowski as Chief Operations Officer (COO). In this new role, Rob will oversee the company’s strategic initiatives across its regulatory, quality, and compliance practice areas, further positioning ELIQUENT to meet the growing global demand for integrated regulatory, quality, and safety solutions across diverse markets.

“Rob’s expertise in building consulting practices and fostering client relationships aligns with ELIQUENT’s commitment to delivering innovative, high-quality solutions to meet the evolving needs of clients,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences.

A seasoned life sciences executive and Non-Executive Director (NED) board member, Rob brings an extensive background in leadership, strategic consulting, and global business growth. As COO, Rob will work closely with the ELIQUENT leadership team to strengthen the firm’s global presence and drive the expansion of ELIQUENT’s service offerings, while ensuring seamless integration of regulatory, quality, and compliance solutions.

Prior to joining ELIQUENT, Rob served for more than six years as Senior Vice President at Syneos Health (Previously INC Research/inVentiv Health) - a leading biopharmaceutical solutions organization that provides comprehensive, integrated services across the entire product lifecycle, from clinical trials to commercialization.

Rob also brings over 20 years of senior leadership experience, including two years as a Non-Executive Director at Sharpview Ophthalmology and key positions at INC Research, Kendle, PPD, and GSK. His roles have been focused on innovation, operational delivery and advancing global research and development across the pharmaceutical, biotechnology, and medical device sectors.



 Àüü´º½º¸ñ·ÏÀ¸·Î

IFF¡¯s 2024 Do More Good Report Highlights Progress in Sustainability and Innovation
L&F Maintains Shipment Growth, Confident in Achieving Profit Turnaround in Q3
Nucleus Network Acquires Hammersmith Medicines Research
Access Advance Extends Founding Licensee Incentives for Video Distribution Patent Pool Through September 30, 2025
Guidewire Niseko Release Delivers Financial and Risk Insights, Bringing Unprecedented Clarity Into Business Performance
Skechers Responds to Kizik¡¯s Patent Lawsuit
Visa Expands Stablecoin Settlement Support

 

Telness Tech Appoints Octopus Group Chairman John Browett to Board of ...
Andersen Consulting Enhances Organizational Development Capabilities w...
LevelBlue Completes Acquisition of Aon¡¯s Cybersecurity and IP Litigat...
Anchorage Digital Partners with Ethena Labs to Launch the First GENIUS...
Brinley Forms $4 Billion Partnership with Leading Insurer, Launches $1...
Esri, Microsoft, and Space42 Join to Launch ¡°Map Africa Initiative¡±
LG ZonaSeru: Bringing the Future of Customer Experiences to Life in In...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..